Jubilant Pharmova Limited · NSE:JUBLPHARMA
Jubilant Pharmova — Q1 FY22 Earnings Presentation
18 slides from Jubilant Pharmova's earnings presentation, Jul 23, 2021
Slide 1: Financial Results Quarter Ended June 30, 2021
Financial Results Quarter Ended June 30, 2021
Slide 2: Disclaimer
Disclaimer Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates f
Slide 3: Conference Call Details
Conference Call Details Date : July 23, 2021 Time : 05:00 pm IST Replay: July 23 to July 30, 2021 Dial-in: +91 22 7194 5757/ +91 22 6663 5757 Playback ID: 96086# 22
Slide 4: Chairmen's Message
Chairmen’s Message Jubilant Pharmova Q1'FY22 Particulars (Rs Crore) Q1'FY21 Q1'FY22 Total Revenue from Operations 1,156 1,635 EBITDA 183 379 EBITDA margin (%) 15.8% 23.2% Profit After Tax 35 160 PAT margin (%) 3.1% 9.8% EPS (Rs) 2.2 10.1 Commenting on Company’s performance, Mr. Shyam S Bhartia, Chai
Slide 5: Q1'FY22 Results Analysis
4 Jonazmova Q1'FY22 Results Analysis
Slide 6: Q1'FY22 Financial Highlights
Q1'FY22 Financial Highlights2 Particulars1 Q1'FY21 Q1'FY22 YoY (%) Revenue Pharmaceuticals 1,096 1,541 41% Revenue was Rs 1,635 Crore versus Rs 1,156 Crore in Q1'FY21 Contract Research and Development Services 57 88 55% • Pharmaceuticals revenue at Rs 1,541 Crore as compared to Rs Proprietary Nove
Slide 7: Pharmaceuticals Segment Highlights – Q1'FY22 (1/2)
Pharmaceuticals Segment Highlights – Q1'FY22 (1/2) Pharmaceuticals Segment Pharmaceuticals revenue was at Rs 1,541 Crore vs. Rs 1,096 Particulars1 Q1'FY21 Q1'FY22 YoY (%) Crore in Q1'FY21 Revenue 1,096 1,541 41% Specialty Pharma 534 632 18% Specialty Pharmaceuticals2 CDMO 279 474 70% Generics 282
Slide 8: Pharmaceuticals Segment Highlights – Q1'FY22 (2/2)
Pharmaceuticals Segment Highlights – Q1'FY22 (2/2) USFDA Inspection Details CDMO1 Facility Last Inspection • CMO business revenue grew YoY based on strong demand from Montreal, Radiopharma Sep, 2017 customers as well as COVID related deals Montreal, CMO May, 2018 • API business continued to witness
Slide 9: Contract Research and Development Services – Q1'FY22
Contract Research and Development Services – Q1'FY22 Contract Research and Development Services Contract Research and Development Services comprises Particulars1 Q1'FY21 Q1'FY22 YoY (%) Revenue 57 88 55% • Through Jubilant Biosys Limited provides innovative and Reported EBITDA 18 34 90% collaborat
Slide 10: Proprietary Novel Drugs (Jubilant Therapeutics)
Proprietary Novel Drugs (Jubilant Therapeutics) Jubilant Therapeutics is a patient-focused biopharmaceutical company working to address unmet medical needs in oncology and autoimmune diseases, with first-in-class and best-in-class programs transitioning to clinic over the next 12-18 months. www.ju
Slide 11: Debt Profile
Debt Profile Particulars 31-Mar-21 30-Jun-21 Foreign Currency Loans (US$ m) (US$ m) Subsidiaries 350 350 Total 350 350 Foreign Currency Loans (Rs Crore) 2,559 2,602 Rupee Loans (Rs Crore) (Rs Crore) Standalone 0 0 Subsidiaries 41 29 Total 41 29 Gross Debt (Rs Crore) (Rs Crore) Standalone 0 0 Subsidi
Slide 12: Business outlook
Business outlook Pharma: In radiopharma, we continue to build a long term pipeline of radiopharmaceuticals and are executing a turnaround plan of radiopharmacies. In CMO, we have a strong visible order book. We are expanding Spokane capacity by 50% that will come into commercial operations by end
Slide 13: Corporate Announcement
Corporate Announcement 12 12
Slide 14: Corporate Announcement
Corporate Announcement The Board of Directors of Jubilant Pharmova Limited (“JPM”), at its meeting held on July 23, 2021, has Board approved the demerger of the Active Pharmaceutical Ingredients (API) undertaking of Jubilant Generics Approval for Limited (“JGL” - a wholly owned subsidiary of the Com
Slide 15: The reorganisation will ensure presence across the value chain
The reorganisation will ensure presence across the value chain Patent Life On -patent Off Patent Type of Discovery Development Commercialization Service Research Discovery Preclinical Clinical Registration Manufacturing Drug Drug discovery DMPK Phase I trials Approval Pharmacological Permission to O
Slide 16: Appendix
4 Jonazmova Appendix 15
Slide 17: Income Statement – Q1'FY22
Income Statement – Q1'FY222 Particulars1 Q1'FY21 Q1'FY22 YoY (%) Total Revenue from Continuing Operations 1,156 1,635 41% Pharmaceuticals 1,096 1,541 41% Contract Research and Development Services 57 88 55% Proprietary Novel Drugs 4 0 - Unallocable Corporate Income 0 5 NA EBITDA from Continuing Oper
Slide 18: For more information
For more information For Investors: Hemant Bakhru | Pavleen Taneja Siddharth Rangnekar Ph: +91 120 436 1002| 21 CDR India E-mail: hemant.bakhru@jubl.com Ph: +91 +91 9769919966 pavleen.taneja@jubl.com E-mail: siddharth@cdr-india.com For Media: Clayton Dsouza Sudhakar Safaya Madison Public Relations P